TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04654988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine: 2 mg/kg daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prednisone
Description: Placebo Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Azathioprine
Description: Placebo Azathioprine
Study: NCT04957862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Assisted Evacuation
Description: On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
Study: NCT05889884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended maxillary fixed retainer
Description: Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
Study: NCT05794048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinoma
Description: Tumor and liver biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic adenocarcinoma
Description: Tumor and pancreatic biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic neuroendocrine tumor
Description: Tumor and pancreatic biopsy
Study: NCT04786379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Irrigation and Debridement
Description: Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Arthrotomy with irrigation and debridement
Description: Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
Study: NCT05238025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tris Buffered Saline (TBS)
Description: One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
Study: NCT06239467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily
Study: NCT03843463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Escitalopram tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic escitalopram 10 mg tablet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered naming treatment
Description: 15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-delivered naming treatment
Description: 15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
Study: NCT06365710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation program
Study: NCT06239467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous (IV)
Study: NCT06365710

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Guided rehabilitation program with physiotherapist appointments
Study: NCT06186427

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-GPFAPI-04 PET/CT
Description: The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
Study: NCT06239467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous (IV)
Study: NCT05476835

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: respiratory exercises - incentive spirometer - walking
Description: respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
Study: NCT05756777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Dose level (-1) 80mg, (1) 120mg, (2) 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Dose level (-1) 80mg, (1) 120mg, (2) 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Dose level (-1) 250mg, (1) 250mg, (2) 500mg
Study: NCT05756777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Dose level (-1) 50mg, (1) 50mg, (2) 100mg
Study: NCT05629689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
Study: NCT05713474

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic EMG exam with microEMG
Description: Diagnostic EMG exam with microEMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic EMG exam with microEMG
Description: Diagnostic EMG exam with microEMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG

Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG
Study: NCT05293028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F527
Description: 0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
Study: NCT05629689

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
Study: NCT05133128

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples
Study: NCT05629689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part B
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
Study: NCT05801575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) teabag
Description: Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) teabag
Description: Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) teabag
Description: Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (CHM) teabag
Description: Each teabag contains five herbs: Radix et Rhizoma (三七, Sanqi), Moutan Cortex (牡丹皮, Mudanpi), Puerariae Lobatae Radix (葛根, Gegen), Rosae Rugosae Flos (玫瑰花, Meiguihua), and Citri Grandis Exocarpium (化橘紅, Huajuhong). These herbs are benefit to promoting blood circulation, dredging meridians and collaterals, strengthening spleen, regulating qi and decreasing phlegm in Chinese Medicine theories.
Study: NCT05771558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored Lighting Intervention (TLI)
Description: The lighting intervention will provide high circadian stimulation produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system.
Study: NCT04931823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound
Study: NCT06012890

Intervention type: OTHER
Intervention: Automation of cardiac MRI acquisition
Description: The intervention will consist of the automation of the cMRI examination.
Study: NCT06093165

Intervention type: RADIATION
Group type: OTHER
Intervention: Re-irradiation
Description: 20Gy on 10 fractions

Intervention type: RADIATION
Group type: OTHER
Intervention: Re-irradiation
Description: 20Gy on 10 fractions
Study: NCT04990869

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06345729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral tablets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT05977426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
Study: NCT05647525

Intervention type: DIAGNOSTIC_TEST
Intervention: Perform autoimmune encephalitis titer tests
Description: We only follow up without intervention.
Study: NCT05605509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP-6306
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Dose and schedule will be assigned at enrolment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Protocol
Description: Irinotecan Leucovorin FU
Study: NCT05448963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci SPⓇ Single-port System
Description: Nipple-sparing mastectomy with or without axillary lymph node dissection using da Vinci SP single-port system
Study: NCT05605509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: standard doses q3weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RP-3500
Description: Dose and schedule will be assigned at enrolment
Study: NCT05505474

Intervention type: DEVICE
Intervention: IVF with the Neria™ Guard Subcutaneous Catheter
Description: Use of the Neria™ Guard subcutaneous catheter for administration of subcutaneous medication in an IVF cycle.
Study: NCT05771558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph
Description: An actigraph is a wrist worn devices that measures rest and activity.
Study: NCT05265715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low AGE diet
Description: The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
Study: NCT05865457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BUFY02 eye drops in single-dose containers
Description: 1 to 2 drops in each eye, as often as needed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRB02 eye drops in single-dose containers
Description: 1 to 2 drops in each eye, as often as needed
Study: NCT06467708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)
Description: This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve. Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
Study: NCT05999240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]
Description: Participants will be randomized to take a single dose of either pimavanserin 34 mg or placebo at Visit 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Pimavanserin Tartrate 34 Mg ORAL CAPSILE \[NUPLAZID\]
Study: NCT06477198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QLB
Description: The block procedure will be applied after the surgery and before extubation with patients in the prone position by using US (Vivid Q, GE Healthcare, US). Under aseptic conditions, the convex probe will be covered with a sterile sheath and a 22G, 80 mm block needle (Braun Stimuplex Ultra 360, Germany) will be used. After visualizing the quadratus lumborum muscle, the needle will be punctured and 5 ml of saline will be injected into the posterior border of the quadratus lumborum muscle between QLM and latissimus dorsi muscle.. After the block location is confirmed, 30 ml of 0.25% bupivacaine will be injected. The same process will be applied to the opposite side (60 ml totally).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: ESP block will be performed. Convex probe will be placed longitudinally 4 cm lateral to the L3 transverse process. Erector spinae muscle will be visualized on the hyperechoic transverse process. The block needle will be inserted cranio caudal direction and then for correction of the needle, 2 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for the block in each side (total 60 mL).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. Tramodol will be performed for rescue analgesia.
Study: NCT06077760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IM injection
Study: NCT06307431

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT05063357

Intervention type: DRUG
Group type: OTHER
Intervention: 131I-Omburtamab
Description: Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).

Intervention type: DEVICE
Group type: OTHER
Intervention: Convention Enhanced Delivery
Description: The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.
Study: NCT04694989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386
Description: QD, PO
Study: NCT06307431

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IM injection